Cytosorbents (NASDAQ:CTSO) Now Covered by WBB Securities

WBB Securities initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a note issued to investors on Wednesday, Marketbeat reports. The brokerage set a “moderate buy” rating and a $9.50 price target on the medical research company’s stock. WBB Securities‘s target price would indicate a potential upside of 65.22% from the stock’s current price.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a research report on Friday, October 2nd. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Cytosorbents currently has an average rating of “Hold” and a consensus target price of $74.83.

Cytosorbents Stock Performance

CTSO stock traded up $0.40 during trading on Wednesday, hitting $5.75. 64,307 shares of the company’s stock traded hands, compared to its average volume of 13,530. The company has a quick ratio of 0.50, a current ratio of 0.66 and a debt-to-equity ratio of 4.70. Cytosorbents has a 52 week low of $2.84 and a 52 week high of $17.28. The stock has a fifty day moving average price of $5.61 and a two-hundred day moving average price of $8.11. The stock has a market capitalization of $18.12 million, a price-to-earnings ratio of -0.99 and a beta of 1.37.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.73. Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 431.65%. The firm had revenue of $9.63 million during the quarter, compared to analyst estimates of $9.39 million. As a group, equities analysts anticipate that Cytosorbents will post -4.40 EPS for the current fiscal year.

Insider Activity at Cytosorbents

In other news, CEO Phillip Chan purchased 200,000 shares of the stock in a transaction dated Friday, September 4th. The stock was acquired at an average price of $0.35 per share, for a total transaction of $70,000.00. Following the completion of the transaction, the chief executive officer owned 1,944,432 shares of the company’s stock, valued at approximately $680,551.20. The trade was a 11.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 7.80% of the company’s stock.

About Cytosorbents

CytoSorbents Corporation is a medical device company that develops blood purification technologies designed to remove harmful substances from the bloodstream. Its products use proprietary, porous polymer adsorbent technology to reduce circulating cytokines, inflammatory mediators, toxins and other substances associated with serious illness.

The company’s principal product, CytoSorb, is an extracorporeal blood purification device used in critical care and other clinical settings. It is designed to help manage excessive inflammation and is used with existing blood-pumping systems.